New injection shows promise for Hard-to-Treat leukemia
NCT ID NCT07246707
First seen Jan 11, 2026 · Last updated Apr 30, 2026 · Updated 16 times
Summary
This early-stage study tests a new drug called KSV01 in 30 adults with a type of blood cancer (B-ALL) that has come back or not responded to standard treatments. The main goal is to check if the drug is safe and what side effects it may cause. Researchers will also look for early signs that the drug is working.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-ALL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
First Affiliated Hospital of Zhejiang University
RECRUITINGHangzhou, China
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.